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The first substantive step in the immune system story was the discovery of autoantibodies (auto-Abs) against the GluR3 subtype of the glutamate receptors in Rasmussen encephalitis, a rare and severe inflammatory progressive epileptic encephalopathy. 2 Although a role for this antibody was later disproven, the report led to the introduction of immunotherapy (IT) in some pharmacoresistant epileptic (PRE) syndromes 3 and incited an intensive search for auto-Abs in epilepsy. The discoveries of limbic encephalitides (LE) associated with auto-Abs against neuronal plasma membrane (receptors, ion channels) or intracellular proteins have further fueled this search. Since seizures are a key manifestation of LE, these disorders serve as a model for understanding the epilepsy-immune system interaction, 4 raising the possibility that such antibodies could cause seizures in patients with epilepsy alone, and leading to the search for auto-Abs in patients with PRE. 5 In fact, a recent prospective study found antineuronal auto-Abs in nearly 10% of pediatric patients with new-onset seizures, a rate more than twice that found in controls with other systemic illnesses. 6 The consequences of testing positive for these auto-Abs are unclear, given that their direct pathophysiologic roles in epileptogenesis are unknown. A similar dilemma is faced by psychiatrists with regards to psychosis, another feature of LE that may rarely occur in isolation. 7 Studies looking for auto-Abs in patients with psychosis or schizophrenia have yielded conflicting results. A conclusive answer requires prospective studies in patients with strictly defined new-onset psychosis. 8 The study of auto-Abs in PRE faces a similar dilemma and requires a similar approach. A fundamental question is whether patients with possible auto-Ab-associated PRE warrant a trial of IT. Should they be treated with medications like corticosteroids, immunoglobulins (IVIg), plasmapheresis, or steroid-sparing drugs (like azathioprine), and, if needed, even more aggressive treatment with cyclophosphamide or the anti-pre-B-lymphocyte monoclonal antibody rituximab? These treatments are associated with severe adverse effects, high costs, and substantial logistics. Thus, the burden of IT must be weighed against that of missing a potentially treatable cause of PRE. This challenge is made greater by the difficulty in objectively assessing patient outcomes, as there are no reliable biomarkers of overall seizure activity and titers of antineuronal auto-Abs only inconsistently reflect disease activity.
In this issue of Neurology ® , Toledano et al. 9 present a retrospective single-center study addressing the utility of an IT trial in patients with presumed autoimmune epilepsy. They identified 29 patients with PRE and auto-Abs from their large database of epilepsy patients, 26 of whom had at least one antineuronal auto-Ab. The patients received IV methylprednisolone, IVIg, or both sequentially; rarely, plasmapheresis, azathioprine, or mycophenolate were used. Just over half of patients responded to the first treatment given, and almost half of the nonresponders improved after a second agent was administered. Response rates were higher in patients with antibodies to plasma membrane antigens (93%) than in patients with intracellular antigens or absent antibodies (33%), while treatment delay was a negative prognostic factor. Long-term oral IT led to sustained seizure reduction in .80% of responders over 6 months. These results are consistent with the known response to IT shown by patients with auto-Abs to neuronal surface antigens such as the NMDA receptor. 10 The authors go on to propose a logical management algorithm for such patients that is supported by their own, as well as prior, data.
Although this study's retrospective data collection at a single center is subject to several biases, including referral bias and treatment choice, the authors should be praised for their effort to define a relatively uniform selection algorithm for patients with a presumed autoimmune PRE. Despite this algorithm, the patient population is still heterogeneous, with differences in auto-Ab type and variation in disease duration. This heterogeneity perhaps makes the robust treatment response even more compelling. A major limitation of this study is the authors' imprecise quantification of their key outcome measure: seizure frequency. Instead of baseline seizure numbers, a categorical system (daily/weekly/monthly seizures) is used. Despite these broad categories, numerical reduction of seizure frequency is used to distinguish responders from nonresponders. Furthermore, it remains unclear whether a response to IT can be used to diagnose autoimmune epilepsy. Some patients with a seemingly unambiguous autoimmune disorder did not respond to treatment-do they not have an autoimmune epilepsy? Or are they treatment refractory? In addition, IT has direct antiseizure effects in disorders without a presumed autoimmune basis, such as the treatment of infantile spasms with adrenocorticotropic hormone and prednisone. Use of IT response to diagnose autoimmune epilepsy may therefore lead to both falsepositives and false-negatives.
Despite these limitations, this study is a crucial step toward elucidating the role of IT in patients with presumed autoimmune PRE, and the current retrospective findings justify consideration of a trial of IT in these patients. These results lay the needed foundation for a randomized controlled trial of IT in presumed autoimmune epilepsy, which would compare standardized treatment groups, thereby eliminating biases with regards to treatment choice and disease severity. This study should also pave the way for additional prospective studies regarding the natural history of autoimmune PRE and serves to raise awareness of the role of IT in the treatment of refractory epilepsies.
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